

**UNIMORE**

Maria Paola COSTI &lt;costimp@unimore.it&gt;

**Hi Maria Paola, Insights and Opportunities in Our Second COST Action Newsletter**

1 messaggio

**OneHealthDrugs COST Action** <onehealthdrugs.events@gmail.com>

27 febbraio 2024 alle ore 11:50

Rispondi a: onehealthdrugs.events@gmail.com

A: mariapaola.costi@unimore.it

If you can't see this newsletter properly, please click [here](#)[Action Site](#) [COST Action](#) [LinkedIn](#) [YouTube](#) [X-Twitter](#)**In this edition ...**

- [Action needed]: **Please complete the First Exploitation Interest survey**
- **Connect, Collaborate, Catalyze: Join the OneHealthdrugs LinkedIn Group!**
- **OHD Women in STEM** Video as featured on **COST Open**

- **OHD** Past & Upcoming OHD events
  - **OHD** Dissemination activities
  - Grant applications
  - Other Initiatives
  - **OHD** available positions
- 

February 26<sup>th</sup>, 2024

Dear Maria Paola ,

You hold in your hands our second edition, a testament to our shared dedication and progress. This newsletter highlights the latest achievements and insights from our diverse, vibrant Community.

As we continue to build and share our collective knowledge, we invite you to contribute to our upcoming editions. Whether it's a fascinating **research post**, **academia / industry news**, **job and fellowship placements**, or other **insightful content** such as upcoming **events**, **grant announcements**, or **request for collaborations**, your input is invaluable. Please send your contributions to us via email till March 15, and let's make our next newsletter a rich repository of our community's achievements and opportunities. All you have to do is to click the button below.

Warm regards,  
the OneHelathDrugs Team

I wish to share with the OHD Community

---

## Message from the Action Chair

---

by [Maria-Paola Costi](#), Action Chair

Dear Esteemed Members,

I am reaching out to highlight the importance of your participation in our [First Exploitation Interest Survey](#). Your insights gathered through this survey are vital for steering our collective efforts and initiatives.

Furthermore, I am thrilled to reiterate our presence on LinkedIn. Our **brand new LinkedIn group** is not just a networking platform; it's a space for us to engage in meaningful discussions, share breakthroughs, and collaborate on innovative

projects. Joining this group will amplify our collective voice and visibility in the wider scientific community.

In addition, I am delighted to share another exciting development. Our video posted at the top, 'Women in Science' has been prominently featured at [COST Live Blog](#), showcasing our commitment to diversity and inclusion in the scientific realm. This feature is a testament to the **impactful work** and dedication of our members. I encourage you to watch, share, and take pride in this significant achievement.

Thank you for your active participation and for contributing to the vibrant dynamism of our COST Action community.



Click on the banner or the video on the side to watch the OHD video for the Women in Science day.

In this link to view COST featuring our video at [LIVE BLOG: gender equality month 2024](#)

**[Action Needed]: Please complete the First Exploitation Interest survey and join our brand new LinkedIn group**

---

---

Central to our mission is the enhancement of the **OHD Compound Database (OHD-DB)**, a cornerstone of our Memorandum of Understanding, a catalyst for fostering meaningful collaborations both within and extending beyond OHD CA21111.

Your expertise and input are key to achieving our strategic objectives:

- **Broaden our Compound Reach:** Your active participation in the coordinated screening of compounds is critical. It's not just about expanding our database, but about spearheading innovation in the crucial area of anti-parasitic drug discovery.
- **Maximise One Health Impact:** We rely on your unique perspectives to deepen our understanding of compound design and screening. Your insights have the power to drive significant advancements in the impact of One Health Drugs.

Another integral reason for your participation in the survey is to **consolidate our human capital**. This is about more than just gathering data; it's about uniting our diverse expertise and experiences to form a robust, cohesive consortium. Your input helps us map the vast array of skills and knowledge within our community, enabling us to harness our collective strength more effectively.

Moreover, this survey serves as your **platform to express interest in EU funding programmes**. This is more than just a survey; it's our gateway to initiating successful grant applications and forming impactful consortia, potentially involving our members.

Understanding the importance of this, we are ready to organise a dedicated meeting to support your interests in these areas. Engage with your colleagues, discuss potential projects, and let's turn these conversations into concrete

actions.

Completing this survey is not only beneficial—it's essential for catalysing grant applications and fostering stronger connections within our OHD network. Your response is a crucial step in supporting our activities and enhancing the synergy among our members.

---

**Connect with us on LinkedIn to strengthen our sense of Community, where your engagement contributes to shaping a vibrant, collaborative Scientific Network.**



**Join the OneHealthdrugs LinkedIn Group!**

Our LinkedIn group is meant to foster collaboration, communication, and knowledge-sharing among us, ultimately enhancing our collective efforts towards the success of our project. Here are a few ways you can utilize the [LinkedIn group](#):

**Knowledge Sharing.** It's our space where OHD members can share your latest research findings, industry news, and professional insights, fostering a culture of continuous learning and information exchange. **Share Updates.** Whether it's a breakthrough in your research, upcoming events, or relevant articles and resources, feel free to share updates with the group members to keep everyone informed.

**Community Support.** It offers a supportive environment where members can seek advice, share challenges, and celebrate successes, strengthening the sense of community and mutual support. **Engage in Discussions.** Use the group to initiate discussions on topics of interest, seek feedback from fellow members, or exchange insights and perspectives on academic matters related to our project.

**Networking Opportunities.** The LinkedIn group serves as a prime platform for connecting with fellow professionals, allowing members to expand their professional network within and beyond the COST Action community. **Network with Peers.** Connect with other members of our team and expand your professional network within our academic community. **Career Development.** The group can be a valuable resource for career advancement, featuring job postings, mentorship opportunities, and discussions on career paths in our field.

**Collaboration Enhancement.** By engaging on this platform, members can discover potential collaborators, explore new ideas, and initiate projects that could lead to groundbreaking advancements. **Collaborate on Projects.** Explore potential collaborations or opportunities for joint projects within the group, leveraging the diverse expertise and backgrounds of our team members.

**Visibility and Impact.** Participation in our LinkedIn group increases individual and collective visibility, showcasing our community's expertise and achievements to a broader audience.

Join Now



---

## OneHealthDrugs March events

---

Reflecting on our past events, we've seen remarkable collaborations and insights emerge. Looking ahead, our upcoming events promise to further ignite our collective passion and drive for scientific excellence.

Here is a list of the PAST events (February2024)

- WG4 meeting 8th February 2023 14:00-15:00 pm CET (VIRTUAL) organizer Rolf Alexander During

- o WG5 meeting 9 February 2024 2-3 pm CET (VIRTUAL) organizer Alfonso tlatoani Garcia
  - o WG2 meeting 9th February 2024 15:00-16:00 pm CET (VIRTUAL) organizer Theodora Calogeropoulou
  - o HG3 Training school meeting 13/02/2024 11:00-13:00 (VIRTUAL) organizer Sheraz Gul
  - o 6thMC meeting 20th February 2024 14:30-17:30 (VIRTUAL) OUTCOME ENCLOSED
- 

Reflecting on our past events, we've seen remarkable collaborations and insights emerge. Looking ahead, our upcoming events promise to further ignite our collective passion and drive for scientific excellence.

- i. [WG3 WG4 Workshop](#) "Omics technologies as a new tool in ecotoxicology " 5th March 2024 14:00-16:00 (VIRTUAL) (postponed to a new date)
  - ii. HG1 SciComm Meeting 7th March 2024 17:00-18:00 pm CET (VIRTUAL)
  - iii. Core Group meeting 25th March 2024 14:30-16:00 (VIRTUAL)
  - iv. [WG2 HG7 Workshop](#) "Green chemistry approaches and innovative drug delivery systems towards reducing environmental impact in antiparasitic drug discovery" 1 5th March 2024 14:00-17:00pm (VIRTUAL)
  - v. [WG6+WG5 Workshop](#) "Minimising the risk of rapid-onset (cross) resistance in PVBD drug development [strategies to assess the risk of rapid resistance developing]" 18th March 2024 14:00-16:00 pm CET (VIRTUAL)
  - vi. HG2 STSM Grants awarding group meeting 20th March 2024 11:00-13:00 (VIRTUAL)
  - vii. WG1 meeting 27th March 2024 15:00-16:00 pm CET (VIRTUAL)
  - viii. HG4 meeting 28th March 2024 17:00-18:00 pm CET (VIRTUAL)
- 

## EVENTS in progress (UNDER ORGANIZATION)

Upcoming Agenda: Action's Works Unfold. Our current lineup of events, each designed to contribute significantly to our strategic goals and collaborative efforts.

- a. **1st Training School** "*Natural products in parasitic diseases*". June 2024 - 3days school, University of Naples, Naples (Italy) ONGOING
- b. **WG3, WG4, WG6, HG4, HG5 Thematic Workshop** "*Animal friendly and environmentally relevant systems to replace or refine animal tests during drug developmental processes for VBD*" 13S, Porto, Portugal, 14-15 May 2024 ONGOING
- c. **Workshop** "*Medicinal chemistry process within the OneHealth perspective for YRI* " 18 th June 2024 Rome (Italy) ONGOING
- d. **ANNUAL OHD CONFERENCE Conference** - "*Structural and functional drug discovery for vector-borne diseases*". Oxford (UK) 3-5 July 2024 ONGOING

- e. **WG1 WG2 HG7 Thematic Workshop**: "Novel leads and drugs for vector borne diseases: Targets and off targets (toxicity and ecotoxicity) and mechanism of action" **September 19-20 2024, National Hellenic Research Foundation, Athens, Greece**
- f. **2nd Training School** "Cell culture as in vitro models for newly developed drugs against vector borne parasitic diseases within the One Health perspective". **25-27 September 2024 -3days school. University of Warsaw, Poland**

---

## OneHealthDrugs Dissemination activities

---

OHD Action Chair participates at the **D24th Drug Design & Development Seminar (DDDS)**

### 24th Drug Design & Development Seminar (DDDS) 2024



Deutsche Gesellschaft für Parasitologie



OHD Action Chair participates at the [D24th Drug Design & Development Seminar \(DDDS\)](#) of the German Society for Parasitology (DGP) "Combining Efforts towards Human and Animal Parasitic Diseases" taking place on March 12th 15th, at 2024Würzburg, Germany.

Prof. Paola Costiwill take the opportunity to present our network. The Book of Abstract will present the dissemination flyer of our COST Action OHD.

### Joint meeting with PARC SYNnet team

#### What is PARC-SYNNET?

PARC is a [collabora.eu](https://collabora.eu) effort that brings together 200 partners from 29 European countries and aiming to develop next-generation chemical risk assessment to protect human health and the environment. Given its size and scope, PARC aims to play a leading role in European research projects focusing on chemical risk assessment. More [here](#).



*Dear all,*

**Letter from Sonia Namorado.**

*The SYNnet team is very pleased to organize a joint meeting between OneHealthDrugs and the related representatives of*



*PARC WP2, WP3, WP4, WP8 (T8.3) and WP9. For your information the agenda for the meeting is the following:*



- *Introduction and tour de table (5min)*
- *Presentation of OneHealthDrugs activities (15min)*
- *Presentation of selected PARC WP2, WP3, WP4, WP8 (T8.3) and WP9 activities by WP/Task co-leaders (15min)*
- *Discussion on possible synergies (25min)*

I wish to participate in the meeting

## New to the One Health Conversation?



### Learn - [What is One Health?](#)

One Health is an integrated, unifying approach that aims to sustainably balance and optimize the health of people, animals and ecosystems. It recognizes the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and inter-dependent.

The approach mobilizes multiple sectors, disciplines and communities at varying levels of society to work together to foster well-being and tackle threats to health and ecosystems, while addressing the collective need for clean water, energy and air, safe and nutritious food, taking action on climate changes and contributing to sustainable development.

The One Health paradigm forges co-equal, all-inclusive collaborations between animal, plant, environmental and human health arenas, i.e. chemical, engineering and social scientists, dentists, nurses, agricultural/horticulturalists and food producers, wildlife and environmental health specialists and many other related disciplines that fall under its purview. The reader can review a compilation of [organizations that are actively working](#) to advance the One Health paradigm shift and many additional [organizations and individuals](#) that declare support for the concept.

**NOTE:** In the GMAIL environment please scroll to the bottom of your message box and

click '[View Entire Message](#)' to see this full newsletter!!!!!!

---

## One Health Happenings News Notes is prepared and shared by the [One Health Commission \(OHC\)](#)

A U.S. based non-profit organization working globally to 'connect' One Health Stakeholders, to 'create' teams and networks that work together across disciplines to 'educate' about [One Health and One Health issues](#).

View [archived issues](#)

To receive [One Health Happenings](#), add yourself to the OHC international One Health [listserv](#) of over 19,000 global One Health supporters.

### Have One Health news to share with the world?

Submit it (100 words or less) [here](#). Contact the [One Health Happenings Team](#)

---

If you have a 100 words story about OHD,  
please send it to Chiara Borsari by clicking this button

---

## Grant applications

### STSM DEADLINE DELAYED

**STSM 4th call opened on February 1st deadline 31 March 2024. This is the second and final STSM call.**

*More events  
below*

This is the **STSM 4th call**

**Opening: Feb 1<sup>st</sup> 2024**

**Deadline: March 31<sup>st</sup> 24**

This is the second and final STSM call.



Short Term Scientific Fellowships

STSM opening of the 3<sup>rd</sup> application round 1 February -15 March 2024  
<https://www.onehealthdrugs.com/stsm/>

OHD  
ONE HEALTH DRUGS

---

We invite you to explore the list of possible applications and organize your collaboration with our consortium participants but also outside of it.

## 1. HORIZON EUROPE - OHD contact: Anabela Cordeiro

The Horizon Europe Global Health EDCTP3 Joint Undertaking has published its [work programme 2024](#). Calls will open on 18th January with deadline for the first stage on the 4th of April. The call for proposals HORIZON-JU-GH-EDCTP3-2024-01-two-stage covers [six topics](#) for Research and Innovation Actions (RIA). Topics include HIV therapeutics, research on Malaria vaccines, Neglected Tropical Diseases, antimicrobial resistance, vector control, and digital health solutions:

**- HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage:** Research on existing Malaria vaccines and development of new promising candidates

*Expected EU contribution per project:* EUR 15 million

*Indicative budget for the topic:* EUR 30 million.

*Type of Action:* RIA (Research and Innovation Action)

**- HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage:** Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa

*Expected EU contribution per project:* EUR 5 million

*Indicative budget for the topic:* EUR 22 million.

*Type of Action:* RIA (Research and Innovation Action)

**- HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage:** New tools, technologies and approaches for vector control in sub-Saharan Africa

*Expected EU contribution per project:* EUR 6.14 million

*Indicative budget for the topic:* EUR 18.432 million.

*Type of Action:* RIA (Research and Innovation Action)

**- HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage:** Innovative digital health solutions for sub-Saharan Africa

*Expected EU contribution per project:* EUR 5 million

*Indicative budget for the topic:* EUR 20 million.

*Type of Action:* RIA (Research and Innovation Action)

---

Interested in **Innovative Training Networks?**

**OHD contact: Theodora Calogeropoulou and Maria Laura Bolognesi**

ITN supports competitively selected joint research training and/or doctoral programmes, implemented by partnerships of universities, research institutions, research infrastructures, businesses, SMEs, and other socio-economic actors from different countries across Europe and beyond.

Partnerships take the form of collaborative European Training Networks (ETN), European Industrial Doctorates (EID) or European Joint Doctorates (EJD).

More at [https://cordis.europa.eu/programme/id/H2020\\_MSCA-ITN-2020](https://cordis.europa.eu/programme/id/H2020_MSCA-ITN-2020)

---

## Weave

Weave is a **bottom-up cross-European initiative** developed by European research funders – and embedded in Science Europe – to support excellent European collaborative research projects across national and regional borders. Based on the **Lead Agency Principle**, Weave aims to simplify the submission and selection procedure of collaborative project proposals: a European team of **researchers from two to three European countries or regions** that have signed the Weave initiative, submits their joint project proposal to only one research funder (Lead Agency) who is responsible for the entire administrative procedure and scientific evaluation.

Each research funder involved is as such responsible for the payment of its own researchers (i.e. researchers eligible for funding from this research funder). Since Weave will enable **bilateral as well as trilateral scientific cooperation within Europe**, it will contribute to the **realisation of the European Research Area (ERA)**.

- [Belgium \(FWO\)](#)
- [Belgium \(FNRS\)](#)
- [Sweden \(Formas\)](#)
- [Germany \(DFG\)](#)
- [Luxembourg \(FNR\)](#)
- [Switzerland \(SNSF\)](#)
- [Austria \(FWF\)](#)
- [Slovenia \(ARRS\)](#)
- [Poland \(NCN\)](#)
- [Czech Republic \(GACR\)](#)
- [Croatia \(HRZZ\)](#)

---

### Open calls for proposals under Horizon Europe Cluster 1 'Health'.

Under destination 3 "**Tackling diseases and reducing disease burden**" the calls address pandemic preparedness and response:

- [HORIZON-HLTH-2024-DISEASE-08-20](#) (RIA) Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential
- [HORIZON-HLTH-2024-DISEASE-08-12](#) (CSA) Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness

Under destination 5 "**Unlocking the full potential of new tools, technologies and digital solutions for a healthy society**" the call focuses on bio-printing of living cells for regenerative medicine:

- [HORIZON-HLTH-2024-TOOL-11-02](#) (RIA) Bio-printing of living cells for regenerative medicine

Under destination 6 “**Maintaining an innovative, sustainable and globally competitive health industry**” the calls focus on fostering innovation in the health industry:

- [HORIZON-HLTH-2024-IND-06-08](#) (RIA) Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)
- [HORIZON-HLTH-2024-IND-06-09](#) (CSA) Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing - coordinated training and experience exchange for regulators

The deadline to apply to these calls is on **11 April 2024, 17:00 CEST**.

---

and a second reminder from **Maria-Paola Costi**

### **OHD report to fill**

Please remember to fill the OHD report, please find here the [link](#)

Thank you for your commitment to shaping the future of OneHealthdrugs.

---

## **Other Initiatives**

---

Please remember to complete the OHD report. Your contributions to this report are crucial, as they provide a comprehensive overview of our collective progress and achievements. This documentation not only helps in tracking our milestones but also plays a vital role in shaping the future direction of our initiatives.

Click on image below (with the instructions) to open the report

### **FILL IN THE OHD REPORT EACH TIME YOU REACH A RESULT / OUTPUT**

#### **6 PAGES:**

- 1-Co-authored publications**
  - 2-Dissemination meetings funded by the Action**
  - 3-Other outputs / achievements**
  - 4- Projects**
  - 5-Other dissemination activities**
  - 6-Exploitation activities**
-

## PROJECTs under Development (More details will be ready soon)

- DATABASE FILING AND USE

Paper Good Database Management (GDM) practice  
Project on Database building

- DRUG DISCOVERY AND ECOTOX


Paper on Drug Discovery and Ecotoxicology  
Project on Drug Discovery and Ecotoxicology

- STRUCTURAL BIOLOGY and ECOTOX

Project for database formation/collection and ECOTOX impact  
Paper on the topic

- COMPUTATIONAL STUDIES PLAN IS ONGOING

## OHD Leadership Positions available



We are excited to announce open leadership positions within our community. These roles offer a unique opportunity to shape our direction and drive innovation. Your involvement as a leader can make a significant difference, bringing new ideas and perspectives to the forefront. We encourage those passionate about making an impact to step forward and contribute to our collective journey.

Just click on apply now and let us which position you are interested in.





- WG6 Leadership
- WG4-Vice leader
- Young Researcher and Innovators

---

## Give us your valuable feedback

---

We will be pleased to answer any questions you may have or consider suggestions for improving our Community.

Please email us at [onehealthdrugs.events@gmail.com](mailto:onehealthdrugs.events@gmail.com)

Contact us if you have any questions,  
suggestions or you wish to share your news



CA21111 - One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthdrugs)

[Unsubscribe me](#) | [Change my information](#)